Although biochemical recurrence (BCR) anticipates PC progression, the increase in the PSA concentration may be prolonged and does not always lead to clinically apparent metastases [13]; nevertheless, it has been reported that the 5-year risk of clinical progression (CP) in men with BCR ranges from 27% to 60% [12]. This evidence concerns the gene KLK3 and pachyonychia congenita.